Literature DB >> 19048064

Mouse xenograft models vs GEM models for human cancer therapeutics.

Ann Richmond, Yingjun Su.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 19048064      PMCID： PMC2562196          DOI： 10.1242/dmm.000976

Source DB:  PubMed          Journal:  Dis Model Mech        ISSN： 1754-8403            Impact factor:   5.758


× No keyword cloud information.
  18 in total

1.  Weekly paclitaxel plus Herceptin in metastatic breast cancer patients who relapse after stem-cell transplant.

Authors:  J R Sporn; S A Bilgrami
Journal:  Ann Oncol       Date:  1999-10       Impact factor: 32.976

2.  The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.

Authors:  Nicholas Mitsiades; Constantine S Mitsiades; Paul G Richardson; Vassiliki Poulaki; Yu-Tzu Tai; Dharminder Chauhan; Galinos Fanourakis; Xuesong Gu; Charles Bailey; Marie Joseph; Towia A Libermann; Robert Schlossman; Nikhil C Munshi; Teru Hideshima; Kenneth C Anderson
Journal:  Blood       Date:  2002-11-07       Impact factor: 22.113

3.  Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.

Authors:  Richard LeBlanc; Laurence P Catley; Teru Hideshima; Suzanne Lentzsch; Constantine S Mitsiades; Nicholas Mitsiades; Donna Neuberg; Olga Goloubeva; Christine S Pien; Julian Adams; Deepak Gupta; Paul G Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Cancer Res       Date:  2002-09-01       Impact factor: 12.701

Review 4.  Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved.

Authors:  Robert S Kerbel
Journal:  Cancer Biol Ther       Date:  2003 Jul-Aug       Impact factor: 4.742

5.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

Authors:  James C Yang; Leah Haworth; Richard M Sherry; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Seth M Steinberg; Helen X Chen; Steven A Rosenberg
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

6.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

7.  Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.

Authors:  Darren W Davis; Keiji Inoue; Colin P N Dinney; Daniel J Hicklin; James L Abbruzzese; David J McConkey
Journal:  Cancer Res       Date:  2004-07-01       Impact factor: 12.701

8.  Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.

Authors:  Babatunde O Oyajobi; Gregory R Mundy
Journal:  Cancer       Date:  2003-02-01       Impact factor: 6.860

Review 9.  Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development.

Authors:  L R Kelland
Journal:  Eur J Cancer       Date:  2004-04       Impact factor: 9.162

Review 10.  Frontline treatment of multiple myeloma in elderly patients.

Authors:  Philippe Moreau; Cyrille Hulin; Thierry Facon
Journal:  Blood Rev       Date:  2008-06-11       Impact factor: 8.250
View more
  151 in total

Review 1.  Stable isotope-resolved metabolomics and applications for drug development.

Authors:  Teresa W-M Fan; Pawel K Lorkiewicz; Katherine Sellers; Hunter N B Moseley; Richard M Higashi; Andrew N Lane
Journal:  Pharmacol Ther       Date:  2011-12-23       Impact factor: 12.310

2.  Subcutaneous passage increases cell aggressiveness in a xenograft model of diffuse large B cell lymphoma.

Authors:  Rosa Bosch; María José Moreno; Rebeca Dieguez-Gonzalez; María Virtudes Céspedes; Alberto Gallardo; Josep Nomdedeu; Miguel Angel Pavón; Iñigo Espinosa; Maria Antònia Mangues; Jorge Sierra; Isolda Casanova; Ramon Mangues
Journal:  Clin Exp Metastasis       Date:  2012-01-20       Impact factor: 5.150

3.  Magnetic resonance imaging-guided microdialysis cannula implantation in a spontaneous high-grade glioma murine model.

Authors:  Mohamed A Elmeliegy; Angel M Carcaboso; Lionel M L Chow; Ziwei M Zhang; Christopher Calabrese; Stacy L Throm; Fan Wang; Suzanne J Baker; Clinton F Stewart
Journal:  J Pharm Sci       Date:  2011-08-11       Impact factor: 3.534

Review 4.  Mammalian models of chemically induced primary malignancies exploitable for imaging-based preclinical theragnostic research.

Authors:  Yewei Liu; Ting Yin; Yuanbo Feng; Marlein Miranda Cona; Gang Huang; Jianjun Liu; Shaoli Song; Yansheng Jiang; Qian Xia; Johannes V Swinnen; Guy Bormans; Uwe Himmelreich; Raymond Oyen; Yicheng Ni
Journal:  Quant Imaging Med Surg       Date:  2015-10

Review 5.  Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment.

Authors:  Yunlu Dai; Can Xu; Xiaolian Sun; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2017-05-18       Impact factor: 54.564

Review 6.  Polysaccharide-Based Controlled Release Systems for Therapeutics Delivery and Tissue Engineering: From Bench to Bedside.

Authors:  Tianxin Miao; Junqing Wang; Yun Zeng; Gang Liu; Xiaoyuan Chen
Journal:  Adv Sci (Weinh)       Date:  2018-01-08       Impact factor: 16.806

7.  UM-SCC-103: a unique tongue cancer cell line that recapitulates the tumorigenic stem cell population of the primary tumor.

Authors:  John H Owen; Samantha J Hauff; Alice L Tang; Martin P Graham; Michael J Czerwinski; Marcella Kaddoura; Silvana Papagerakis; Carol R Bradford; Thomas E Carey; Mark E P Prince
Journal:  Ann Otol Rhinol Laryngol       Date:  2014-05-09       Impact factor: 1.547

8.  Overview of human primary tumorgraft models: comparisons with traditional oncology preclinical models and the clinical relevance and utility of primary tumorgrafts in basic and translational oncology research.

Authors:  David H Lum; Cindy Matsen; Alana L Welm; Bryan E Welm
Journal:  Curr Protoc Pharmacol       Date:  2012-12

Review 9.  Choosing The Right Animal Model for Renal Cancer Research.

Authors:  Paweł Sobczuk; Anna Brodziak; Mohammed Imran Khan; Stuti Chhabra; Michał Fiedorowicz; Marlena Wełniak-Kamińska; Kamil Synoradzki; Ewa Bartnik; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Transl Oncol       Date:  2020-02-22       Impact factor: 4.243

Review 10.  Circulating tumor cells and CDX models as a tool for preclinical drug development.

Authors:  Alice Lallo; Maximilian W Schenk; Kristopher K Frese; Fiona Blackhall; Caroline Dive
Journal:  Transl Lung Cancer Res       Date:  2017-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.